· Periodic Report
Q3 profit from the main business KRW 1.6 billion, up 2.9% from a year earlier
Central Vaccine sold KRW 11.5 billion in Q3 and earned KRW 1.6 billion from its main business, up 2.9% from a year earlier and 39.3% from the prior quarter.